Induction of remission in myeloblastic and monoblastic leukaemia in adults with rubidomycin.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000667:Ampicillin / Q000627:therapeutic use; D000741:Anemia, Aplastic / Q000139:chemically induced; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001792:Blood Platelets; D001803:Blood Transfusion; D009202:Cardiomyopathies; D002509:Cephaloridine / Q000627:therapeutic use; D004562:Electrocardiography; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008875:Middle Aged; D010292:Paresthesia / Q000139:chemically induced; D012075:Remission, Spontaneous; D013420:Sulfamethoxazole / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced / Q000628:therapy; D014295:Trimethoprim / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D000667:Ampicillin; D014295:Trimethoprim; D015122:Mercaptopurine; D013420:Sulfamethoxazole; D002509:Cephaloridine